Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2023 17:00 ET | Source: Aravive, Inc.

Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
April 11, 2023 07:05 ET | Source: Aravive, Inc.

Aravive Appoints Carolina Petrini as Chief Commercial Officer

HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
March 15, 2023 07:00 ET | Source: Aravive, Inc.

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
February 28, 2023 16:05 ET | Source: Aravive, Inc.

Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer

Dose escalation portion of ongoing Phase 1b/2 pancreatic adenocarcinoma trial initiated, with preliminary results expected in 2H 2023 HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....
February 13, 2023 17:00 ET | Source: Aravive, Inc.

Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
January 04, 2023 07:05 ET | Source: Aravive, Inc.

Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer

Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late...
November 29, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
November 21, 2022 07:00 ET | Source: Aravive, Inc.

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
November 16, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
November 10, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic AdenocarcinomaSecured Funding to Take the Company Beyond the PROC...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right